Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis
Latest Information Update: 07 Nov 2021
At a glance
- Drugs S 524101 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- Sponsors Stallergenes SA
- 21 Jan 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 13 Aug 2013 New trial record